<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have earlier shown that stimulation of endothelin B receptors by IRL-1620 provides significant neuroprotection at 24h following <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the effect of IRL-1620 is not known in the <z:hpo ids='HP_0011011'>subacute</z:hpo> phase of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, where development of <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> further contributes towards brain damage </plain></SENT>
<SENT sid="2" pm="."><plain>This study was designed to determine the effect of IRL-1620 on neurological functions, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, <z:mp ids='MP_0003674'>oxidative stress</z:mp>, and endothelin receptors following permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 7 days </plain></SENT>
<SENT sid="3" pm="."><plain>Rats received three intravenous injections of either vehicle or IRL-1620 [<z:chebi fb="9" ids="37952">Suc-</z:chebi>[Glu9,Ala11,15]-Endothelin-1(8-12)] at 2, 4, and 6h post occlusion </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment with IRL-1620 reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (54.06 ± 14.12 mm(3) vs. 177.06 ± 13.21 mm(3)), prevented <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> and significantly improved <z:hpo ids='HP_0000001'>all</z:hpo> neurological and motor function parameters when compared to the vehicle-treated group </plain></SENT>
<SENT sid="5" pm="."><plain>Vehicle-treated middle cerebral artery occluded rats demonstrated high levels of malondialdehyde and low levels of reduced <z:chebi fb="0" ids="16856">glutathione</z:chebi> and <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase; these effects were reversed in IRL-1620 treated rats </plain></SENT>
<SENT sid="6" pm="."><plain>No change in expression of endothelin A receptor was observed 7 days after induction of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in vehicle or IRL-1620 treated rats </plain></SENT>
<SENT sid="7" pm="."><plain>Rats receiving IRL-1620 demonstrated an upregulation of endothelin B receptor only in the infarcted hemisphere 7 days following occlusion </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> effects of IRL-1620 were blocked by endothelin B receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, BQ788 </plain></SENT>
<SENT sid="9" pm="."><plain>Results of the present study demonstrate that IRL-1620, administered on day 1, provides significant neuroprotection till 7 days after the induction of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="10" pm="."><plain>Selective endothelin B receptor activation may prove to be a novel therapeutic target in the treatment of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>